What is Bright Minds Biosciences Inc.'s (DRUG) StockRank?

MoatMap's StockRank for Bright Minds Biosciences Inc. (DRUG) is 16/100, with a Strong Sell signal. This is a composite score combining Quality (47), Value (26), and Momentum (32) factor ranks across MoatMap's 19,000+ stock universe.

Does Bright Minds Biosciences Inc. have an economic moat?

Bright Minds Biosciences Inc. (DRUG) has a Quality factor score of 47/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Bright Minds Biosciences Inc. a buy, hold, or sell?

MoatMap's current signal for Bright Minds Biosciences Inc. (DRUG) is Strong Sell, based on a StockRank of 16/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Bright Minds Biosciences Inc. in?

Bright Minds Biosciences Inc. (DRUG) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

DRUG

STRONG SELLREMOVE

Bright Minds Biosciences Inc. · Healthcare · United States · $878M · Avg Vol: $22M/d

StockRank

P/E (TTM)

—

ROE

-15.0%

D/E

0.0x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Bright Minds Biosciences is a pre-revenue biotechnology company focusing on neuropsychiatric disorders. It is highly speculative and lacks the validated manufacturing scale or regulatory moats of our preferred CDMO theme.

COMPANY DESCRIPTION

Bright Minds Biosciences Inc. is a biotechnology company focused on developing novel serotonin receptor agonists for the treatment of neuropsychiatric disorders. The company's proprietary small molecule drug candidates aim to selectively target specific serotonin receptor subtypes to address conditions like epilepsy, depression, and pain. It operates as a clinical-stage biotech firm, distinguished by its precision psychiatry approach to developing improved therapies for challenging central nervous system conditions.

FINANCIAL SUMMARY

Year	2022	2023	2024	2025	CAGR
Revenue	0	0	0	0	—
EPS	-6.06	-1.98	-0.65	-1.78	—
Shares	4M	4M	5M	8M	+117.0%
Debt	139,911	73,549	118,960	125,777	-3.5%
Equity	11M	7M	6M	82M	98.2%
Op CF	-14M	-7M	-2M	-9M	—
Inv CF	—	—	—	—	—
Fin CF	5M	2M	810,572	86M	—

PRICE (1M)-28.9%

SMA 50SMA 200

$59.17

RSI (14)

15.0

52W High

$123.75

From 52W High

0.5%

SCORE BREAKDOWN

Quality

ROIC

-17.0%30.0

ROE

-15.0%32.2

GP/Assets

—N/A

Op. Margin

0.0%40.6

FCF/Assets

-11.2%26.6

Piotroski

—28.8

Int. Cover

—N/A

D/E Ratio

0.00x99.1

Current Ratio

81.48x99.6

Value

P/E (TTM)

—N/A

EV/EBITDA

—N/A

P/FCF

—N/A

P/B

3.7x31.8

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

48%21.2

RS 6M

-42%27.9

SMA 50/200

1.13x83.1

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

-253%1.7

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$878M

P/E (Forward)

-7.0x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of DRUG are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
DRUG	Bright Minds Biosciences Inc.(you)	$878M	16	STRONG SELL
XNCR	Xencor, Inc.	$887M	16	STRONG SELL
JANX	Janux Therapeutics, Inc.	$899M	15	STRONG SELL
AVTX	Avalo Therapeutics, Inc.	$848M	17	STRONG SELL
EVMN	Evommune, Inc.	$840M	15	STRONG SELL
KURA	Kura Oncology, Inc.	$885M	19	STRONG SELL
ORIC	ORIC Pharmaceuticals, Inc.	$875M	21	SELL
CTMX	CytomX Therapeutics, Inc.	$808M	21	SELL
SPRY	ARS Pharmaceuticals, Inc.	$933M	10	STRONG SELL
DNA	Ginkgo Bioworks Holdings, Inc.	$618M	16	STRONG SELL

Peer medians: ROE -22.7% · P/E 25.1x · Gross margin 44.3%

Bright Minds Biosciences Inc. (DRUG) — Stock Score Summary

Bright Minds Biosciences Inc. (DRUG) has a MoatMap StockRank of 16/100 based on Quality (47/100), Value (26/100), and Momentum (32/100) factor scores. The current signal is STRONG SELL. Bright Minds Biosciences is a pre-revenue biotechnology company focusing on neuropsychiatric disorders. It is highly speculative and lacks the validated manufacturing scale or regulatory moats of our preferred CDMO theme.

Key Financial Metrics

Price	$59.17
Market Cap	$878M
P/E (Forward)	-7.05
Price/Book	3.75
Return on Equity	-15.0%
Return on Invested Capital	-17.0%
Debt/Equity	0.03
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-9M

Bright Minds Biosciences Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Bright Minds Biosciences Inc.’s (DRUG) StockRank?: MoatMap’s StockRank for Bright Minds Biosciences Inc. (DRUG) is 16/100, with a Strong Sell signal. It is a composite of Quality (47), Value (26), and Momentum (32) factor ranks across MoatMap’s 19,000+ stock universe.
Does Bright Minds Biosciences Inc. have an economic moat?: Bright Minds Biosciences Inc. (DRUG) has a Quality factor score of 47/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Bright Minds Biosciences Inc. a buy, hold, or sell?: MoatMap’s current signal for Bright Minds Biosciences Inc. (DRUG) is Strong Sell, based on a StockRank of 16/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Bright Minds Biosciences Inc. in?: Bright Minds Biosciences Inc. (DRUG) operates in the Healthcare sector, specifically the Biotechnology industry (United States).